EquityZen Growth Technology Fund LLC - Series 1894
Raised
$321K
Investors
16
Min Invest
$5,016
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 1894 is a Delaware pooled investment fund filed by EquityZen Advisors and Phil Haslett, raising $321K from 16 investors under Rule 506(b) and Section 3(c)(1) exemptions. The vehicle requires a $5K minimum investment and is part of the EquityZen platform, which operates over 1,800 related pre-IPO investment entities.
This pre-IPO fund uses the standard 506(b)/3(c)(1) exemption structure typical of private secondary market platforms, with a retail-accessible $5K minimum investment. The $20K average check size and 16-investor count align with EquityZen's established series vehicle model for fractional access to late-stage private company shares.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.